Several of the cannabinoids are reputed to have medicinal potential: THC for glaucoma, spasticity from spinal injury or multiple sclerosis, pain, inflammation, insomnia, and asthma; CBD for some psychological problems. The Netherlands firm HortaPharm developed strains of Cannabis rich in particular cannabinoids. The British firm G.W. Pharmaceuticals acquired proprietary access to these for medicinal purposes, and is developing medicinal marijuana. In the US, NIH (National Institute of Health) has a program of research into medicinal marijuana, and has supplied a handful of individuals for years with maintenance samples for medical usage. The American Drug Enforcement Administration is hostile to the medicinal use of Cannabis, and for decades research on medicinal properties of Cannabis in the US has been in an extremely inhospitable climate, except for projects and researchers concerned with curbing drug abuse. Synthetic preparations of THC—dronabinol (Marinol®) and nabilone (Cesamet®)—are permitted in some cases, but are expensive and widely considered to be less effective than simply smoking preparations of marijuana. Relatively little material needs to be cultivated for medicinal purposes (Small 1971), although security considerations considerably inflate costs. The potential as a “new crop” for medicinal cannabinoid uses is therefore limited. However, the added-value potential in the form of proprietary drug derivatives and drug-delivery systems is huge. The medicinal efficacy of Cannabis is extremely controversial, and regrettably is often confounded with the issue of balancing harm and liberty concerning the proscriptions against recreational use of marijuana. This paper is principally concerned with the industrial uses of Cannabis. In this context, the chief significance of medicinal Cannabis is that, like the issue of recreational use, it has made it very difficult to rationally consider the development of industrial hemp in North America for purposes that everyone should agree are not harmful.
^ Jump up to: a b Deitch, Robert (2003). Hemp: American History Revisited: The Plant with a Divided History. Algora Publishing. pp. 4–26. ISBN 9780875862262. Retrieved 2013-11-16. Cannabis is ... a plant that played an important role in colonial America's prosperous economy and remained a valuable commercial commodity up until the Second World War.
Jump up ^ McLaren JA, Silins E, Hutchinson D, Mattick RP, Hall W (January 2010). "Assessing evidence for a causal link between cannabis and psychosis: a review of cohort studies". The International Journal on Drug Policy. 21 (1): 10–9. doi:10.1016/j.drugpo.2009.09.001. PMID 19783132. The contentious issue of whether cannabis use can cause serious psychotic disorders that would not otherwise have occurred cannot be answered based on the existing data
Cannabis drug preparations have been employed medicinally in folk medicine since antiquity, and were extensively used in western medicine between the middle of the 19th century and World War II, particularly as a substitute for opiates (Mikuriya 1969). A bottle of commercial medicinal extract is shown in Fig. 41. Medical use declined with the introduction of synthetic analgesics and sedatives, and there is very limited authorized medical use today, but considerable unauthorized use, including so-called “compassion clubs” dispensing marijuana to gravely ill people, which has led to a momentous societal and scientific debate regarding the wisdom of employing cannabis drugs medically, given the illicit status. There is anecdotal evidence that cannabis drugs are useful for: alleviating nausea, vomiting, and anorexia following radiation therapy and chemotherapy; as an appetite stimulant for AIDS patients; for relieving the tremors of multiple sclerosis and epilepsy; and for pain relief, glaucoma, asthma, and other ailments [see Mechoulam and Hanus (1997) for an authoritative medical review, and Pate (1995) for a guide to the medical literature]. To date, governmental authorities in the US, on the advice of medical experts, have consistently rejected the authorization of medical use of marijuana except in a handful of cases. However, in the UK medicinal marijuana is presently being produced sufficient to supply thousands of patients, and Canada recently authorized the cultivation of medicinal marijuana for compassionate dispensation, as well as for a renewed effort at medical evaluation.
But recent activity in Washington has legislators in every aisle waving banners for hemp. So far, 20 states have stepped up to encourage industrial hemp production.5 On February 7, 2014, the 2013 Farm Bill6 was signed into law, legitimizing industrial hemp as distinct, and authorizing university and State departments of agriculture (where it’s legal) for research or pilot programs. On January 8, 2015, The Industrial Hemp Farming Act of 2015, S. 134, was introduced in the U.S. Senate.
Research suggests that CBD may exert some of its pharmacological action through its inhibition of fatty acid amide hydrolase (FAAH), which may in turn increase the levels of endocannabinoids, such as anandamide, produced by the body. It has also been speculated that some of the metabolites of CBD have pharmacological effects that contribute to the biological activity of CBD.
There have been ten clinical trials on the use of inhaled Cannabis in cancer patients that can be divided into two groups. In one group, four small studies assessed antiemetic activity but each explored a different patient population and chemotherapy regimen. One study demonstrated no effect, the second study showed a positive effect versus placebo, the report of the third study did not provide enough information to characterize the overall outcome as positive or neutral. Consequently, there are insufficient data to provide an overall level of evidence assessment for the use of Cannabis for chemotherapy-induced N/V. Apparently, there are no published controlled clinical trials on the use of inhaled Cannabis for other cancer-related or cancer treatment–related symptoms.
Fig. 2. Cannabis sativa. This superb composite plate by artist Elmer Smith, often reproduced at a very small scale and without explanation in marijuana books, is the best scientific illustration of the hemp plant ever prepared. 1. Flowering branch of male plant. 2. Flowering branch of female plant. 3. Seedling. 4. Leaflet. 5. Cluster of male flowers. 6. Female flower, enclosed by perigonal bract. 7. Mature fruit enclosed in perigonal bract. 8. Seed (achene), showing wide face. 9. Seed, showing narrow face. 10. Stalked secretory gland. 11. Top of sessile secretory gland. 12. Long section of cystolith hair (note calcium carbonate concretion at base). Reproduced with the permission of Harvard University, Cambridge, MA.
As provided in Sec. 7606 of the 2014 Farm Bill industrial hemp may only be grown as part of a research or pilot project. The 108th General Assembly enacted Public Chapter 916 regarding the growing of industrial hemp in Tennessee. The Act removes industrial hemp from the definition of marijuana in the criminal code. The cultivation of industrial hemp is now available as an option for Tennessee farmers on a limited basis. The Commissioner of the Tennessee Department of Agriculture has promulgated regulations establishing a program of licensing authorized hemp producers.
Over the ages, countless innovations have attempted to improve on the basic experience of inhaling the smoke of combusted cannabis. As a result, there are numerous ways to smoke marijuana. The rolling technique is at the root of joints, blunts, and spliffs. On the other hand, glassware and other devices are essential for smoking weed out of a pipe, bong, or bubbler.
Industrial hemp may be grown in Montana only by the Montana Department of Agriculture (MDA) through the Industrial Hemp Pilot Program or by institutions of higher education in Montana for agricultural or academic research. Only seed purchased from the Pilot Program seed repository or ordered from a DEA-approved source can legally be planted in Montana. Industrial hemp is currently regulated as a Schedule I Controlled Substance by the federal government. Persons who violate state or federal laws regarding hemp may be subject to federal prosecution under the Controlled Substances Act (CSA). Refer to the DEA website for more information.
An analysis of 84,170 participants in the California Men’s Health Study was performed to investigate the association between Cannabis use and the incidence of bladder cancer. During 16 years of follow-up, 89 Cannabis users (0.3%) developed bladder cancer compared with 190 (0.4%) of the men who did not report Cannabis use (P < .001). After adjusting for age, race, ethnicity, and body mass index, Cannabis use was associated with a 45% reduction in bladder cancer incidence (hazard ratio, 0.55; 95% confidence interval, 0.33–1.00).
CBD may also enhance uptake of cytotoxic drugs into malignant cells. Activation of the transient receptor potential vanilloid type 2 (TRPV2) has been shown to inhibit proliferation of human glioblastoma multiforme cells and overcome resistance to the chemotherapy agent carmustine.  One study showed that coadministration of THC and CBD over single-agent usage had greater antiproliferative activity in an in vitro study with multiple human glioblastoma multiforme cell lines. In an in vitro model, CBD increased TRPV2 activation and increased uptake of cytotoxic drugs, leading to apoptosis of glioma cells without affecting normal human astrocytes. This suggests that coadministration of CBD with cytotoxic agents may increase drug uptake and potentiate cell death in human glioma cells. Also, CBD together with THC may enhance the antitumor activity of classic chemotherapeutic drugs such as temozolomide in some mouse models of cancer.[13,33] A meta-analysis of 34 in vitro and in vivo studies of cannabinoids in glioma reported that all but one study confirmed that cannabinoids selectively kill tumor cells.
Of course, the easiest solution, advocates say, is for the federal government to legalize cannabis completely. If cannabis were legalized—the whole plant and all its extracts, no confusing singling-out of specific compounds or anatomical features—then U.S. drug companies would be able to carefully cultivate and research its medicinal properties, and submit their findings to regulatory bodies like the FDA for trials and approval.
Another study examined the effects of a plant extract with controlled cannabinoid content in an oromucosal spray. In a multicenter, double-blind, placebo-controlled study, the THC:CBD nabiximols extract and THC extract alone were compared in the analgesic management of patients with advanced cancer and with moderate-to-severe cancer-related pain. Patients were assigned to one of three treatment groups: THC:CBD extract, THC extract, or placebo. The researchers concluded that the THC:CBD extract was efficacious for pain relief in advanced cancer patients whose pain was not fully relieved by strong opioids. In a randomized, placebo-controlled, graded-dose trial, opioid-treated cancer patients with poorly controlled chronic pain demonstrated significantly better control of pain and sleep disruption with THC:CBD oromucosal spray at lower doses (1–4 and 6–10 sprays/day), compared with placebo. Adverse events were dose related, with only the high-dose group (11–16 sprays/day) comparing unfavorably with the placebo arm. These studies provide promising evidence of an adjuvant analgesic effect of THC:CBD in this opioid-refractory patient population and may provide an opportunity to address this significant clinical challenge. An open-label extension study of 43 patients who had participated in the randomized trial found that some patients continued to obtain relief of their cancer-related pain with long-term use of the THC:CBD oromucosal spray without increasing their dose of the spray or the dose of their other analgesics.
That being said, it was unlikely that the federal government was interested in pursuing individuals complying with state-mandated regulations surrounding legalized cannabis for recreational use, although the CSA law still gives them authority to do so. However, the new Trump administration may change this thinking and users of legal marijuana and legal dispensaries await further action and clarifying rules.
Mainly what they look for in drug test is THC. Hemp contains only very minuscule amounts of THC. You cannot get high off of hemp. It is impossible. You would have to smoke or eat a boat load of hemp to even remotely get a buzz. A person could not ingest that much hemp, and a person would die of smoke inhalation before smoking enough to achieve a buzz. So hemp does not contain enough THC to show up on a drug screening. I hope this information helps you.
George Washington also imported the Indian Hemp plant from Asia, which was used for fiber and, by some growers, for intoxicating resin production. In a letter to William Pearce who managed the plants for him Washington says, "What was done with the Indian Hemp plant from last summer? It ought, all of it, to be sown again; that not only a stock of seed sufficient for my own purposes might have been raised, but to have disseminated seed to others; as it is more valuable than common hemp."
Despite its designation as having no medicinal use, Cannabis was distributed by the U.S. government to patients on a case-by-case basis under the Compassionate Use Investigational New Drug program established in 1978. Distribution of Cannabis through this program was closed to new patients in 1992.[1-4] Although federal law prohibits the use of Cannabis, Figure 1 below shows the states and territories that have legalized Cannabis use for medical purposes. Additional states have legalized only one ingredient in Cannabis, such as cannabidiol (CBD), and are not included in the map. Some medical marijuana laws are broader than others, and there is state-to-state variation in the types of medical conditions for which treatment is allowed.
Medical reviews published in 2017 and 2018 incorporating numerous clinical trials concluded that cannabidiol is an effective treatment for certain types of childhood epilepsy. An orally administered cannabidiol solution (brand name Epidiolex) was approved by the US Food and Drug Administration in June 2018 as a treatment for two rare forms of childhood epilepsy, Lennox-Gastaut syndrome and Dravet syndrome.
According to researchers, 25 percent of all cancer patients use medical marijuana. Cancer patients are finding relief from medical cannabis. And they want to know more about it. Research conducted at St. George’s University of London, found the two most common cannabinoids in marijuana, tetrahydrocannabinol (THC) and cannabidiol (CBD), weakened the ferocity of cancer cells and made them more susceptible to radiation treatment. Other studies have shown that medical marijuana treatments can slow the growth of cancer cells and halt their spread to other parts of the body.
Because of its high THC-content, in most parts of the world, including the US, Marijuana is illegal. Seeing the massive economical and medicinal benefits that Marijuana can provide, some countries and states in the US have legalized Marijuana. As the political landscape changes, hopefully more will follow, but as of now, Marijuana is generally illegal.
The confusion compounds when one realizes that in today’s popular lexicon, the terms indica, sativa, and hybrid tend to indicate a set of effects, rather than the taxonomy of a particular strain. But that’s just as well. Most marijuana strains today, especially those under commercial cultivation, are genetic hybrids. Only a handful of pure, or “landrace” cannabis strains are in circulation.
CBD oil 4% is a medium-strength, organic formulation. Now, you can supplement with the confidence of a king or queen! If you are already familiar with CBD and find you require a little more than what's offered by our 2.5% formulation, this is the CBD oil for you. CBD oil 4% is derived from EU hemp strains bred for a high CBD content. Natural, GMO-free, and non-psychoactive. Available now in convenient 10, 30 and 50ml dropper bottles.
Since Cannabis smoke contains many of the same components as tobacco smoke, there are valid concerns about the adverse pulmonary effects of inhaled Cannabis. A longitudinal study in a noncancer population evaluated repeated measurements of pulmonary function over 20 years in 5,115 men and women whose smoking histories were known. While tobacco exposure was associated with decreased pulmonary function, the investigators concluded that occasional and low-cumulative Cannabis use was not associated with adverse effects on pulmonary function (forced expiratory volume in the first second of expiration [FEV1] and forced vital capacity [FVC]).
The use of Cannabis as a mind-altering drug has been documented by archaeological finds in prehistoric societies in Eurasia and Africa. The oldest written record of cannabis usage is the Greek historian Herodotus's reference to the central Eurasian Scythians taking cannabis steam baths. His (c. 440 BCE) Histories records, "The Scythians, as I said, take some of this hemp-seed [presumably, flowers], and, creeping under the felt coverings, throw it upon the red-hot stones; immediately it smokes, and gives out such a vapour as no Grecian vapour-bath can exceed; the Scyths, delighted, shout for joy." Classical Greeks and Romans were using cannabis, while in the Middle East, use spread throughout the Islamic empire to North Africa. In 1545, cannabis spread to the western hemisphere where Spaniards imported it to Chile for its use as fiber. In North America, cannabis, in the form of hemp, was grown for use in rope, clothing and paper.
The U.S. hemp-derived CBD market alone is projected to reach $450 million by 2020, and China's cannabis market could grow to 100 billion yuan by 2022 (approximately $14.5 billion). Hemp is already interwoven into the futures of the automotive, construction, energy, environmental mediation and technology industries. Once fully utilized and legal, this plant could impact the global economic positionings of North America, China and Africa.
In addition to providing useful fibers, hemp seed also has high nutritional value. and the plant can be used to make biodegradable plastics, some fuels, and a variety of other things. Hemp foods including but not limited to hemp energy bars, hemp salad dressing,hemp milk, hemp protein shakes, hemp oil gel caps and hemp protein powder are among some of the health products being produced today. Visit the Hemp Education pages to learn more!
Cannabis has held sacred status in several religions. It has been used in an entheogenic context – a chemical substance used in a religious, shamanic, or spiritual context - in the Indian subcontinent since the Vedic period dating back to approximately 1500 BCE, but perhaps as far back as 2000 BCE. There are several references in Greek mythology to a powerful drug that eliminated anguish and sorrow. Herodotus wrote about early ceremonial practices by the Scythians, thought to have occurred from the 5th to 2nd century BCE. In modern culture the spiritual use of cannabis has been spread by the disciples of the Rastafari movement who use cannabis as a sacrament and as an aid to meditation. The earliest known reports regarding the sacred status of cannabis in the Indian subcontinent come from the Atharva Veda estimated to have been written sometime around 2000–1400 BCE.
Cannabis impairs psychomotor performance in a wide variety of tasks, such as motor coordination, divided attention, and operative tasks of many types; human performance on complex machinery can be impaired for as long as 24 hours after smoking as little as 20 mg of THC in cannabis; there is an increased risk of motor vehicle accidents among persons who drive when intoxicated by cannabis.
Cannabis use for medicinal purposes dates back at least 3,000 years.[1-5] It was introduced into Western medicine in 1839 by W.B. O’Shaughnessy, a surgeon who learned of its medicinal properties while working in India for the British East India Company. Its use was promoted for reported analgesic, sedative, anti-inflammatory, antispasmodic, and anticonvulsant effects.
Hemp is completely different from marijuana in its function, cultivation and application. But these differences didn’t stop our political leaders from getting confused and accidentally grouping all Cannabis species as a Schedule I Drug and banning it in 1970 under the Controlled Substances Act. Even after 45 years, the government still seems to have some confusion in distinguishing the two plants. Although legislation is being made, progress has been slow.In its application, hemp and marijuana serve completely different purposes. Marijuana, as it is widely known, is used for medicinal or recreational purposes. Hemp is used in variety of other applications that marijuana couldn’t possibly be used in. These include healthy dietary supplements, skin products, clothing, and accessories. Overall, hemp is known to have over 25,000 possible applications.
At least 50% of patients who receive moderately emetogenic chemotherapy may experience delayed chemotherapy-induced N/V. Although selective neurokinin 1 antagonists that inhibit substance P have been approved for delayed N/V, a study was conducted before their availability to assess dronabinol, ondansetron, or their combination in preventing delayed-onset chemotherapy-induced N/V. Ondansetron, a serotonin 5-hydroxytryptamine 3 (5-HT3) receptor antagonist, is one of the mainstay agents in the current antiemetic armamentarium. In this trial, the primary objective was to assess the response 2 to 5 days after moderately to severely emetogenic chemotherapy. Sixty-one patients were analyzed for efficacy. The total response–a composite endpoint–including nausea intensity, vomiting/retching, and use of rescue medications, was similar with dronabinol (54%), ondansetron (58%), and combination therapy (47%) when compared with placebo (20%). Nausea absence was greater in the active treatment groups (dronabinol 71%, ondansetron 64%, combination therapy 53%) when compared with placebo (15%; P < .05 vs. placebo for all). Occurrence rates for nausea intensity and vomiting/retching episodes were the lowest in patients treated with dronabinol, suggesting that dronabinol compares favorably with ondansetron in this situation where a substance P inhibitor would currently be the drug of choice.
Hemp plants can be vulnerable to various pathogens, including bacteria, fungi, nematodes, viruses and other miscellaneous pathogens. Such diseases often lead to reduced fiber quality, stunted growth, and death of the plant. These diseases rarely affect the yield of a hemp field, so hemp production is not traditionally dependent on the use of pesticides.